+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Handbook of Neuroemergency Clinical Trials. Edition No. 2

  • ID: 4226379
  • Book
  • December 2017
  • Region: Global
  • 400 Pages
  • Elsevier Science and Technology
1 of 3

Handbook of Neuroemergency Clinical Trials, Second Edition, focuses on the practice of clinical trials in acute neuroscience populations, or what have been called neuroemergencies. Neuroemergencies are complex, life-threatening diseases and disorders, often with devastating consequences, including death or disability. The overall costs are staggering in terms of annual incidence and costs associated with treatment and survival, yet despite their significance as public health issues, there are few drugs and devices available for definitive treatment. The book focuses on novel therapies and the unique challenges their intended targets pose for the design and analysis of clinical trials.

This volume provides neurologists, neuroscientists, and drug developers with a more complete understanding of the scientific and medical issues of relevance in designing and initiating clinical development plans for novel drugs intended for acute neuroscience populations. The editors provide the best understanding of the pitfalls associated with acute CNS drug development and the best information on how to approach and solve issues that have plagued drug development.

  • Presents a comprehensive overview on clinical trials and drug development challenges in acute neuroscience populations
  • Provides neurologists, neuroscientists and drug developers with a complete understanding of scientific and medical issues related to designing clinical trials
  • Edited by leaders in the field who have designed and managed over 50 neuroemergency clinical trials
Note: Product cover images may vary from those shown
2 of 3

ACUTE ISCHEMIC STROKE 1. Acute Ischemic Stroke 2. Subarachnoid Hemorrhage 3. Clinical Trials in Spontaneous Intracerebral Hemorrhage 4. Imaging Biomarkers in Stroke Trials

TRAUMATIC BRAIN INJURY 5. Traumatic Brain Injury 6. Improving approaches to evaluate efficacy and safety of drugs for traumatic brain injury 7. Brain Imaging in Traumatic Brain Injury 8. The Use of Blood-Based Biomarkers to Improve the Design of Clinical Trials of Traumatic Brain Injury 9. Biostatistical Issues in TBI Clinical Trials

SEIZURE EMERGENCIES 10. Acute Seizures and Status Epilepticus 11. Post-traumatic Seizures

NONTRAUMATIC NEUROEMERGENCIES 12. Neuroemergencies in Critical Care Patients 13. Neuro-Emergency Clinical Trials: Migraine 14. Acute Visual Deficits

DEVICES FOR NEUROEMERGENCIES 15. Implications for new trials in acute ischemic stroke in the new era of endovascular therapy

KEY ISSUES IN NEUROEMERGENCY CLINICAL TRIALS 16. The Role of a Project Medical Officer in Acute Neuroemergency Clinical Studies 17. Regulatory Considerations 18. Military Perspectives on Brain Injuries: Implications for Clinical Trials

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Skolnick, Brett E.
Dr. Skolnick is a Clinical Associate Professor of Neurosurgery at North Shore-LIJ School of Medicine in Manhasset, New York. He has a broad based experience with development responsibilities in neurology that includes Intracerebral hemorrhage, traumatic brain injury and stroke as well as more recently in the area of inflammation having worked on the development of multiple monoclonal antibodies in Psoriasis, Rheumatoid Arthritis, Crohn's disease and Ulcerative Colitis. Dr. Skolnick has previously worked as a clinical development consultant to pharmaceutical companies with a focus on early novel drug development.
Alves, Wayne M.
Dr. Alves is Vice President of Clinical Operations at Evoke Pharmaceuticals, Inc. in Solana, California. He has held academic positions conducting basic clinical research in neuroemergency populations, and has served as consultant to numerous companies seeking to develop novel drugs.
Note: Product cover images may vary from those shown